Immuron Ltd — Regulatory Filings 2006

Jul 23, 2006

July 24th, 2006

Company Announcement Office Australian Stock Exchange Ltd (ASX) 4^th Floor, 20 Bridge Street Sydney NSW 2000

Dear Sir/Madam

Please find herewith a company announcement "African Distributor Appointed For Travelan" for release and distribution to the market immediately.

Yours sincerely

CONOR GRAHAM Managing Director & CEO

ANADIS LIMITED ABN 80 063 114 045 4 Capital Link Drive Campbellfield Victoria Australia 3061 Ph (61) 3 9358 6388 Fax (61) 3 9358 6399 email: info@anadis.com.au website: www.anadis.com.au

PHARMACO appointed as Travelan distributor for African Continent

Anadis to pleased announce the appointment of Pharmaco Distribution Pty Ltd, as the exclusive distributor for Travelan across the African continent. Pharmaco has an extensive distribution and marketing network throughout Africa with its Head Office in South Africa, a subsidiary in the Ivory Coast, and regional offices in Cameroon and Senegal.

Anadis anticipates the first order shortly, with a minimum sales target for the first twelve months of almost a quarter of a million packets. This benchmark is set to rise to over 325,000 packets by year three.

Pharmaco has undertaken the commitment to market and promote Travelan and will be responsible for all marketing activities across the African continent. Travelan is to be targeted at both the internal travellers and those from abroad.

Currently Pharmaco is the South African distributor for a number of large international clients including: Roche, Abbott, ICN/Valeant, Sanofi Pasteur, United Pharmaceuticals and Bioniche.

The appointment of Pharmaco Distribution is a result of the continued effort to establish a global presence for Travelan. Travelan now has distributors appointed in Canada and Africa, with Singapore, Taiwan and the US expected in the near future.

More information about Pharmaco Distribution Pty Ltd can be found at http://www.pharmaco.co.za/

Travelan

Travelan, a natural, medically proven pre-emptive product, is available without prescription. This revolutionary preparation has been scientifically and medically proven to significantly reduce a person's risk of getting the medical condition known as travellers' diarrhoea.

Travelan contains naturally derived antibodies against the 13 strains of E. coli that are the most common cause of travellers' diarrhoea (TD). These specific antibodies bind to the bacteria in the intestinal tract, significantly minimizing the bacteria's ability to bind to the intestinal wall, thus shielding the user from TD. Travelan is a not an antibiotic, therefore not associated with the usual negative antibiotic side effects.

Travelan enables the traveler, or for those who dine out, to do so with significantly reduced risk of becoming ill due to exposure to very common E. coli bacteria.

In hospital clinical trials in the US and Europe, Travelan has shown up to 90% protection against Enterotoxigenic E, coli (ETEC), the main cause of Travellers' Diarrhoea.

Travelers' Diarrhoea (TD)

TD, otherwise known as: Tourista, Delhi Belly, Montezuma's Revenge, Trots etc., is described as the number one (1) health problem for international travelers in terms of frequency and economic impact.

According to Government and Medical sources, the symptoms of TD include:

• Abdominal bloating, cramps $\&$ pains
• Nausea
• Diarrhoea
• $\bullet$ Fever

Potential Additional Gastrointestinal Indications for Travelan

Anadis is now investigating the use of Travelan for additional gastrointestinal therapeutic indications as a result of positive clinical feedback from a number of healthcare providers, including medical specialists.

Reports to the company indicate that a number of patients with a range of gastrointestinal conditions, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and ulcerative colitis, have experienced an improvement in some their symptoms (e.g. diarrhoea) whilst taking Travelan to reduce their risk of contracting travellers' diarrhoea.

For more information please visit www.travelan.com.

About Anadis Limited:

Anadis, a Melbourne based biopharmaceutical company is focused on Nutraceutical and Pharmaceutical research and development. Anadis is a specialist in the development of specific antibody products for therapeutic use in humans.

Projects include:

Travelan - Anadis' first commercialised product, is a natural product which significantly decreases the risk of the medical condition known as Travellers Diarrhoea, and also the symptoms of gastrointestinal disorders. Travelan is a specific antibody preparation, against the 13 most common strains of E.coli – the most common cause of Travellers Diarrhoea

Travelan has recently received a "Green Light' for sales in North America and a distributor in Canada has been appointed, followed soon by a US distributor. Travelan is also being prepared for other markets including: Singapore,

India, Korea, United Arab Emirates, Thailand, Malaysia the UK and EU.

Travelan has also recently been potentially identified for additional gastrointestinal indications including Irritable Bowel Syndrome IBS and Inflammatory Bowel Disorder IBD.

For more information please visit www.travelan.com.

EV-71 - a bioactive protein based preventative product against Enterovirus 71, a debilitating polio like disease, is one of the viruses that causes 'hand, foot and mouth' or 'slapped cheek' disease in children. A significant proportion of effected younger children can develop nervous signs such as fits, others paralysis or even death.

A set of Bio-Warfare/Respiratory Protection technologies, a project in conjunction with the Australian Department of Defence and US Bio-Defence Organisations, initially focused on short-term immediate protection from airborne bacteria such as Anthrax and Plague, future civilian applications include Hay Fever and Asthma.

Bio-Shield 10 a range of "bio-shielding" technologies which protect delicate molecules, enzymes and proteins, initially targeted for use in the pro-biotic market and emerging oral vaccine markets.

Development into an Immune Stimulating Infant Formula is underway, initially destined for the Asian market.

Pyloran, which has been clinically proven to reduce levels of H.pylori bacteria in the stomach and reduce the symptoms of $H.$ pylori associated gastritis - Anadis is also in early development of a H.pylori vaccine.

For further information, please contact:

Conor Graham - Chief Executive Officer Email: conor.g@anadis.com.au +61 3 9358 6388

Arie Nudel - Investor Relations Email: $\arceq$ . $\alpha$ anadis. com. au +61 3 9358 6388

Visit our websites: www.anadis.com.au and www.travelan.com.au

Anadis - Delivering On The Promise Of Biotechnology